MSIP and NYEE Launch iLABS, Featuring the Latest Technology in Ophthalmic Care
The inaugural iLABS event took place on September 19, showcasing the latest technologies in ophthalmology from Mount Sinai Health System innovators. Hosted by the Mount Sinai Department of Ophthalmology, the New York Eye and Ear (NYEE) Infirmary Program for Innovation and Technology, …
Sinai BioDesign Hosts FDA Representative to Discuss Medical Device Submissions
Sinai BioDesign, an organization of the Icahn School of Medicine at Mount Sinai focused on the development of biomedical technologies, hosted U.S. Food and Drug Administration (FDA) representative Joshua Chetta on October 1 to discuss the regulations and requirements for device submission …
EKF Diagnostics Holding plc Announces Preferred Partner Arrangement with Mount Sinai
Opportunity to support digital health platform for Inflammatory Bowel Disease September 10, 2019 — EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has entered into a non-exclusive Preferred Partner Arrangement with Mount Sinai Innovation Partners (MSIP). MSIP is …
Moving Science into the Clinic
How Mount Sinai Drives Real-World Applications of Research Discoveries By Douglas McCormick From the fall issue of Mount Sinai Science & Medicine magazine The long-anticipated combination of artificial intelligence and molecular biology is now producing personalized, precision treatments for patients at Mount …
Life Science Academic Partnerships Part 1: an Ideal Marriage to Fuel Organic Growth
By Mark Ralph, Executive Director & Global Head, Contracts & Alliance Management, Boehringer Ingelheim Pharmaceuticals, Inc. In today’s innovation environment, external collaboration is one of the most powerful methods to discover and develop new treatments and research tools, particularly between industry and …
FDA Grants Breakthrough Device Designation to KidneyIntelX™
Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ – Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted Breakthrough Device designation by the U.S. Food …
HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics
$60.75M funding round led by ARCH Venture Partners with 6 Dimensions Capital HiberCell will build on pioneering tumor dormancy research conducted by the Julio Aguirre-Ghiso Lab at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai HiberCell, a …
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
New York, NY (January 15, 2019) – The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate sodium for the treatment of mucopolysaccharidosis (MPS), with Australia-based company Paradigm Biopharmaceuticals Ltd. (ASX: PAR) …
Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind
New York, NY (December 04, 2018) — Sema4, a patient-centered predictive health company, and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors …